BioNTech SE (BNTX)
BioNTech develops immunotherapies for cancer and infectious diseases and sells the COVID-19 vaccine Comirnaty. It last closed at $80.96 on Nov 20, down 0.52% on the day. Over the last 12 months BNTX insiders bought $0 of stock on the open market and sold $89.8M, according to SEC Form 4 filings.
Key Stats
Fiscal 2025Not reported for this period.
From BNTX's SEC filings, latest 20-F/A for the period ending Dec 31, 2025 (filed Jul 30). Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on BNTX
Technical AnalysisPrices may be delayed
The stock is 7% below its 20 day and 13% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot S1 at $79.86, and the nearest resistance the Pivot at $81.36.
| RSI (14) | 31.46 | Weak, oversold below 30 | Neutral |
| MACD | -2.50 | Below its signal line | Bearish |
| Stochastic | 4.2 | Near the bottom of its range | Oversold |
| ADX (14) | 19.1 | No clear trend | |
| Williams %R | -93.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -208.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −7.5% | Change over 10 sessions | Bearish |
| ATR (14) | $2.65 | Typical daily range, 3.3% of price |
| RSI (14) | 37.40 | Weak, oversold below 30 | Neutral |
| MACD | -3.01 | Below its signal line | Bearish |
| Stochastic | 4.3 | Near the bottom of its range | Oversold |
| ADX (14) | 14.5 | No clear trend | |
| Williams %R | -98.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -140.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −16.3% | Change over 10 sessions | Bearish |
| ATR (14) | $7.63 | Typical daily range, 9.4% of price |
What happened before
See how BNTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BNTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options FlowPrices may be delayed
90DNo whale options trades in BNTX in the last 90 days.
Dark PoolPrices may be delayed
30DBNTX Institutional Ownership
Full report →- ▲147 buying vs 125 selling
- ●Shares held by funds +0.1%
- ▲Funds holding +20
- ▲Superinvestors: 3 added, 1 cut
- ▲Put/call 1.05 to 0.20
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 304 | 284 | +7.0% |
| In funds' top 10 | 5 | 5 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 57 / 90 | 39 / 91 | +13.1% |
| Reduced / sold out | 88 / 37 | 72 / 30 | +22.5% |
| Put/call ratio | 0.20 | 1.05 | −80.7% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
BNTX Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 9 | Ugur SahinCEO | Sale plan | 63,209 | $94.07 | $5.9M |
| Oct 7 | Ugur SahinCEO | Sale plan | 24,000 | $95.86 | $2.3M |
| Oct 6 | Ugur SahinCEO | Sale plan | 93,000 | $97.14 | $9.0M |
| Oct 2 | Ugur SahinCEO | Sale plan | 34,000 | $97.09 | $3.3M |
| Sep 30 | Ugur SahinCEO | Sale plan | 66,000 | $98.19 | $6.5M |
| Sep 28 | Ugur SahinCEO | Sale plan | 61,000 | $98.57 | $6.0M |
From SEC Form 4 filings by BNTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BNTX is in one of them and how their past BNTX trades turned out.
BNTX News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BNTX in an article yet. Here's the latest on the wider market.
- BioNTech to Acquire US FDA Priority Review Voucher
- Interim Condensed Consolidated Statements of Profit or Loss
- BioNTech Announces Third Quarter 2026 Financial Results
- BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
- BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
- BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
BNTX Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Valerie HoyleD · OR | Sell | $1K – $15K | Aug 7, 2025 | Sep 12, 2025 | 36 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Sep 3, 2024 | Oct 3, 2024 | 30 d |
| Josh GottheimerD · NJ | Sell (partial) | $1K – $15K | Aug 30, 2024 | Sep 11, 2024 | 12 d |
| Josh GottheimerD · NJ | Buy | $1K – $15K | Apr 15, 2024 | May 15, 2024 | 30 d |
| Josh GottheimerD · NJ | Sell | $1K – $15K | Mar 14, 2024 | Apr 7, 2024 | 24 d |
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About BioNTech SE
BioNTech is a biotechnology company based in Mainz, Germany, that develops medicines based on the immune system. Its main focus is cancer, with further work on vaccines and therapies for infectious diseases, using messenger RNA and protein-based technologies. Its marketed product is Comirnaty, a COVID-19 vaccine sold through partners such as Pfizer and Fosun Pharma in many countries. Its customers are mainly public health authorities and healthcare systems that buy vaccines. Most of its other products are still being tested in clinical trials.
- Headquarters
- Mainz, Germany
- Founded
- 2008
- Website
- biontech.de ↗





